Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer

NCT03809624 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

160

Enrollment

INDUSTRY

Sponsor class

Stopped Program terminated due to lack of meaningful efficacy signal.

Conditions

Metastatic Solid Tumors
Non-small Cell Lung Cancer
Melanoma
Head and Neck Squamous Cell Carcinoma
Gastric Adenocarcinoma
Renal Cell Carcinoma
Esophageal Adenocarcinoma
Nasopharyngeal Carcinoma
Oropharyngeal Carcinoma

Interventions

DRUG: INBRX-105 - PDL1x41BB antibody
DRUG: Pembrolizumab

Sponsor

Inhibrx Biosciences, Inc